These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone. Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study. Dominguez S; Ghosn J; Peytavin G; Izzedine H; Wirden M; Ktorza N; Miller M; Aubron-Olivier C; Trylesinski A; Calvez V; Deray G; Katlama C J Med Virol; 2007 Feb; 79(2):105-10. PubMed ID: 17177308 [TBL] [Abstract][Full Text] [Related]
4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
5. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients. Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104 [TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT. Chappell BJ; Margot NA; Miller MD AIDS; 2007 Mar; 21(6):761-3. PubMed ID: 17413698 [TBL] [Abstract][Full Text] [Related]
8. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Squires K; Pozniak AL; Pierone G; Steinhart CR; Berger D; Bellos NC; Becker SL; Wulfsohn M; Miller MD; Toole JJ; Coakley DF; Cheng A; Ann Intern Med; 2003 Sep; 139(5 Pt 1):313-20. PubMed ID: 12965939 [TBL] [Abstract][Full Text] [Related]
9. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. Miller MD; Margot N; Lu B; Zhong L; Chen SS; Cheng A; Wulfsohn M J Infect Dis; 2004 Mar; 189(5):837-46. PubMed ID: 14976601 [TBL] [Abstract][Full Text] [Related]
10. Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations. Hsu R; Lanier ER; Rouse EG; Oie KL; Pappa KA; Ross LL Antivir Ther; 2008; 13(5):735-7. PubMed ID: 18771059 [TBL] [Abstract][Full Text] [Related]
12. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up. Clevenbergh P; Durant J; Halfon P; del Giudice P; Mondain V; Montagne N; Schapiro JM; Boucher CA; Dellamonica P Antivir Ther; 2000 Mar; 5(1):65-70. PubMed ID: 10846595 [TBL] [Abstract][Full Text] [Related]
13. K65R, TAMs and tenofovir. Miller MD AIDS Rev; 2004; 6(1):22-33. PubMed ID: 15168738 [TBL] [Abstract][Full Text] [Related]
14. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Hazra R; Gafni RI; Maldarelli F; Balis FM; Tullio AN; DeCarlo E; Worrell CJ; Steinberg SM; Flaherty J; Yale K; Kearney BP; Zeichner SL Pediatrics; 2005 Dec; 116(6):e846-54. PubMed ID: 16291735 [TBL] [Abstract][Full Text] [Related]
15. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V; J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728 [TBL] [Abstract][Full Text] [Related]
16. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF; Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392 [TBL] [Abstract][Full Text] [Related]
17. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load. Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G; J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879 [TBL] [Abstract][Full Text] [Related]
18. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients. Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827 [TBL] [Abstract][Full Text] [Related]
19. Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic. Péré H; Charpentier C; Mbelesso P; Dandy M; Matta M; Moussa S; De Dieu Longo J; Grésenguet G; Abraham B; Bélec L AIDS Res Hum Retroviruses; 2012 Apr; 28(4):315-23. PubMed ID: 21942692 [TBL] [Abstract][Full Text] [Related]
20. The potential place of tenofovir in antiretroviral treatment regimens. Gazzard BG Int J Clin Pract; 2001 Dec; 55(10):704-9. PubMed ID: 11777298 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]